Darin Lippoldt sold $1.7M of NBIX
Chief Legal Officer at NEUROCRINE BIOSCIENCES INC. 10,000 shares at an average of $170.15, traded Jun 26, 2026, filed Jun 30, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.7M at market
- +5Share of holdings soldSold 18% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001504783-26-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | MOption exercise Common Stock10b5-1 | +200 | $81.49 | $16k | 54,929 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $169.57 | $34k | 54,729 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +8,110 | $81.49 | $661k | 62,839 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stock10b5-1 | -8,110 | $170.03 | $1.4M | 54,729 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +1,690 | $81.49 | $138k | 56,419 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stock10b5-1 | -1,690 | $170.81 | $289k | 54,729 | Jun 30, 2026 |
| Jun 26, 2026 | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -200 | $0.00 | $0 | 24,765 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -8,110 | $0.00 | $0 | 16,655 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -1,690 | $0.00 | $0 | 14,965 | Jun 30, 2026 |
Related signals
Other insiders at NEUROCRINE BIOSCIENCES INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | NEUROCRINE BIOSCIENCES INC | Matt Abernethy Chief Financial Officer | $363k 2,311 shares | -5% | |
| 21Weak | NEUROCRINE BIOSCIENCES INC | David W. Boyer Chief Corp. Affairs Officer | $130k 826 shares | -9% | |
| 10Weak | NEUROCRINE BIOSCIENCES INC | Eric Benevich Chief Commercial Officer | $333k 2,154 shares | -3% | |
| 3Weak | NEUROCRINE BIOSCIENCES INC | Leslie Norwalk V director | $228k 1,250 shares | -44% | |
| 15Weak | NEUROCRINE BIOSCIENCES INC | Ingrid Delaet Chief Regulatory Officer | $791k 4,367 shares | -21% | |
| 18Weak | NEUROCRINE BIOSCIENCES INC | Darin Lippoldt Chief Legal Officer | $1.8M 10,000 shares | -15% | |
| 33Weak | NEUROCRINE BIOSCIENCES INC | Ingrid Delaet Chief Regulatory Officer | $2.6M 14,571 shares | -74% | |
| 40Moderate | NEUROCRINE BIOSCIENCES INC | Stephen A Sherwin director | $4.1M 25,000 shares | -61% | |
| 32Weak | NEUROCRINE BIOSCIENCES INC | Leslie Norwalk V director | $210k 1,250 shares | -31% | |
| 40Moderate | NEUROCRINE BIOSCIENCES INC | Julie Cooke Chief Human Resources Officer | $5.8M 36,937 shares | -62% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.